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Research Article
Discovery of potential DNA methylation
markers for forensic tissue identification
using bisulphite pyrosequencing
The presence of specific body fluids at crime scenes could be linked with particular types
of crime, therefore attributing a DNA profile to a specific tissue could increase the eviden-
tial significance of a match with a suspect. Current methodologies such as tissue-specific
mRNA profiling are useful but drawbacks include low tissue specificity and applicabil-
ity to degraded samples. In this study, the potential of 11 tissue-specific differentially
methylated regions, initially identified following large-scale methylation analysis of whole
blood, buccal cells and sperm, was explored in order to identify markers for blood, saliva
and semen. Bisulphite pyrosequencing analysis supported previous findings, but tissue-
specific differentially methylated regions for blood and buccal cells did not show enough
specificity to be proposed as markers for blood and saliva, respectively. For some CpGs, a
large inter-individual variation in methylation levels was also observed. Two of the semen
markers (cg04382920 and cg11768416) were used for further validation on a large set of
stains. These two semen-specific assays showed high sensitivity (as low as 50 pg) and
stability. Future experiments will shed light on the usefulness of these markers in forensic
casework.
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1 Introduction
The weight of forensic scientific evidence could be enhanced
in court if the cellular origin of a body fluid stain was identi-
fied. Alongside DNA typing, information regarding the cellu-
lar origin of a recovered biological stain would be very benefi-
cial if attempting to reconstruct events that have taken place
at a crime scene. The presence of specific body fluids could
be linked with particular types of crime, for example the pres-
ence of semenmight indicate sexual assault. However, some-
times it is very difficult, if not impossible, to attribute a DNA
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profile recovered from a stain to a specific body fluid type,
limiting the evidential significance of a match. New solutions
are needed to eliminate doubts as to whether the presence
of an obtained DNA profile is a truly meaningful event in
the context of the case, or simply the result of an unrelated,
‘innocent’ contact.
While forensic mRNA profiling using tissue-specific
mRNA markers is a useful confirmatory test due to its great
sensitivity and potential applicability [1, 2], it does not come
without drawbacks. Issues have been raised regarding tissue-
to-tissue specificity and its applicability in extensively de-
graded samples where RNA is more difficult to obtain. Such
constraints are particularly important when re-examining
‘cold cases’, where only DNA has been retained and current
methods cannot be used. A method that would exploit tissue-
specific variations in the stability of DNA molecule would be
helpful overcoming the limitations of existing methods and
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providing a direct link between the recovered DNA and its
source.
It is known that epigenetics, and specifically DNAmethy-
lation, is one of the main mechanisms responsible for cell
differentiation and differential gene expression [3, 4]. Re-
searchers have investigated how DNA methylation regulates
gene expression, which is mostly by silencing (or in some
cases activating) gene transcription [5]; furthermore, there are
various published studies investigating large-scale methyla-
tion patterns across various tissues that have either revealed
tissue-specific [6, 7] or age-associated CpG sites [8, 9]. There-
fore, differential DNA methylation patterns could offer an
important alternative to mRNA profiling when differentiat-
ing forensically relevant tissues. Indeed, Frumkin et al. were
the first to explore the possibility of DNA methylation-based
forensic tissue identification [10]. Following initial screen-
ing of 200 CpG islands, a total of 38 genomic loci demon-
strated differential amplification signals, 15 of which were
subsequently used in a proposed tissue identification as-
say. Even though variability in methylation ratios, due to
inter-individual variation or stochastic PCR effects, was ob-
served, authors suggested that each tissue type had a distinct
methylation profile. Further analysis also revealed that 100%
identification could be achieved by using only seven of the
15 loci. The proposed method would also be very promising
as a forensic application since it utilises the same platform
used in standard STR profiling; however, incomplete diges-
tion by the methylation-sensitive restriction enzyme could
also lead to erroneous results. Furthermore, methylated loci
not amplified because of degradation in aged samples could
be mistakenly identified as unmethylated.
In addition, Wasserstrom et al. [11] developed a DNA
methylation-based semen test (Nucleix DSI-Semen kit),
which tested whether five genomic loci could be used to suc-
cessfully distinguish between semen and non-semen sam-
ples with high accuracy. While a comprehensive validation
study on the kit’s performance illustrated that the required
starting DNA material can be as low as 62 pg [12], a test that
could simultaneously identify all body fluids would be prefer-
able. In another study, Lee et al. tested previously reported
tissue-specific differentially methylated regions (tDMRs) and
proposed a different methodological approach that included
bisulphite sequencing [13]. As the authors suggested, two pre-
viously reported testis-specific DMRs (DACT1 and USP49)
could be applied for semen identification, the presence of
an unmethylated HOXA4 tDMR could possibly be used to
exclude the presence of blood, while PFN3 tDMR could
potentially be useful for the identification of vaginal secre-
tions. Although the results were promising and were vali-
dated by two more sensitive multiplex assay systems [14], sex
differences and inter-individual variations were once again
observed.
It is evident that, with the exception of semen, de-
termining highly tissue-specific tDMRs utilising CpG sites
for the rest of the biologically more complex body fluids,
such as saliva, still remains a challenge. While recent ef-
forts have identified new potential markers for forensic use,
mainly fromgenome-wideDNAmethylation data [15–17], the
identification of more suitable CpG sites would be ben-
eficial. The ability to test multiple tissue-specific CpG
sites per body fluid/tissue is needed in addition to deal
with problems associated with inter-individual variation and
mixtures.
The aim of this study was to identify novel tissue-specific
differentially methylated CpG sites by analysing published
methylation data obtained fromblood, semen and buccal cells
and subsequently validating their respective methylation lev-
els through bisulphite pyrosequencing. The specificity and
sensitivity of promising markers was evaluated by testing a
large set of samples from a wide range of tissues and body
fluids as well as aged stains.
2 Materials and methods
2.1 Sample collection
Biological samples included in this study were collected
following full ethical approval by the appropriate Research
Ethics Subcommittee at King’s College London (BDM RESC
13/14-30). Full informed consent was obtained from all
donors prior to sample collection. In total, 100 volunteers of
both sexes and various ethnic backgrounds with ages ranging
from 16 to 70 years participated in this study. Individuals had
the choice to donate one or more body fluids/tissues includ-
ing whole blood, saliva, buccal cells, seminal fluid, vaginal
fluid, menstrual secretion, skin, and urine. Up to 20 mL of
whole blood were collected by a trained phlebotomist in a
clinical setting. Buccal cell samples were collected by rub-
bing a buccal swab in the inner cheeks for 20 s (mainly con-
taining buccal cells), while saliva samples were collected by
depositingmouth liquid (1mL) in a suitable receptacle (that
could contain other non-epithelial cells or compounds, such
as white blood cells). All other body fluid samples were col-
lected either using a cotton swab or a suitable receptacle by the
participants in the privacy of their homes. Information such
as subject’s gender, ethnicity and age were also recorded if
possible. For validation purposes, a set of aged samples pre-
viously collected were also used, including semen samples
stored at –20°C for 16 years and dried bloodstains stored at
ambient temperature for 20–21 years.
2.2 DNA sample preparation
Depending on the type of sample and size/quantity, avail-
able genomic DNA was extracted using either the QIAamp
DNA Investigator kit (Qiagen) or the BioRobot EZ1
R©
DNA
Investigator kit (Qiagen) according to themanufacturer’s rec-
ommendations. To assess the quantity of DNA in the result-
ing solution, samples were quantified using the Quantifiler
R©
Human DNA Quantification kit (ThermoFisher Scientific)
according to the protocol. In order to convert differences
in DNA methylation to differences in DNA sequence, DNA
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samples are treated with sodium bisulphite, which converts
unmethylated cytosines into uracil, while themethylated ones
remain unchanged. In this study, the MethylEdge Bisul-
fite Conversion kit (Promega) was applied. The kit speci-
fies that the method can be used for 100 pg–2 g starting
DNA material (optimal range 200–500 ng), providing DNA
recovery of around 80%. For the purpose of this study, de-
pending on the sample type 1–100 ng of each DNA sample
was converted using the ‘modified conversion protocol’ as
suggested by the manufacturer. The amount of DNA to be
treated depended on the experiment and availability (espe-
cially in the cases of aged stains); for example, to test the
specificity of the selected markers, a total of 1 ng of each
DNA sample was used for bisulphite conversion, while to
test the sensitivity of the assays decreasing amounts (as
low as 10 pg) were used. Bisulphite-treated DNA samples
were eluted in 20 L of elution buffer and stored at –20°C
for up to 1 month. Together with the samples, pre-defined
DNA methylation controls (0–100%) (EpigenDx) were also
used in order to assess both bisulphite conversion efficiency
and the linearity of methylation quantification of selected
assays.
2.3 Selection of candidate CpG markers
Combining available data from two studies analysed by differ-
ent large-scale methodologies for three forensically relevant
tissues (whole blood, buccal cells and sperm), the methyla-
tion status of a total of 3305 CpGs was obtained. Data were
normalised using appropriate methods in order to account
for batch effects or study-to-study technical variations as pre-
viously described [6, 8]. Methylation data for seven blood and
two sperm samples were recovered from the study by Rakyan
et al. [6], while methylation values for ten buccal swabs were
gathered from Rakyan et al. [8]. No data were available for
body fluids like vaginal fluid and menstrual blood, therefore
it was decided that these tissues would be included in the
validation phase only.
2.4 Bisulphite Pyrosequencing R© assay design
In this study, primers were designed to amplify bisulphite-
treated DNA; design parameters needed to be adjusted to
account for the generally low efficiency of bisulphite PCR,
common mis-priming events as well as the non-specific am-
plification due to the T-richness of the bisulphite-treatedDNA
sequences. There is various primer design software designed
for methylation analysis; however, the online tool BiSearch
was considered as most suitable and selected for assay de-
sign. Its search algorithm has the unique ability of analysing
the proposed primer pairs for potential mis-priming sites
and therefore resulting non-specific amplification products
on both bisulphite-treated DNA strands. [18]. A total of
12 assays were designed to investigate the CpG sites iden-
tified through the analysis of genome-wide methylation data;
each bisulphite Pyrosequencing
R©
assay includes a 10× PCR
primer set (forward and reverse) as well as a 10× sequencing
primer. Although we were interested only in these 12 CpG
sites, assay design allowed for the co-analysis of a few adja-
cent CpG sites per assay resulting in the investigation of a
total of 48 analysed CpGs. To simplify data analysis, the as-
says were named according to the tissue they were specific
for (BL for blood, SE for semen and BU for buccal cells) and
if they were expected to be unmethylated (-U-) or methylated
(-M-) in that specific tissue. For example, the blood methy-
lated marker 1 (BLM1) (cg13763232) assay indicates that the
investigated CpG site is expected to be methylated in blood,
while being unmethylated in semen and buccal cell sam-
ples. Sequential numbers were used to indicate different CpG
sites being examined. Information regarding all designed as-
says is presented in Table 1 and Supporting Information
Table 1.
2.5 Amplification of bisulphite-converted DNA
In this study, ZymoTaq premix (Zymo Research) was
utilised as it contains a heat-activated, “hot start” DNA poly-
merase that reduces the occurrence of non-specific prod-
uct or primer–dimer formation when amplifying bisulphite-
converted DNA. Starting with the standardised PCR
conditions suggested by the manufacturer, all bisulphite
PCR assays were optimised before analysis in order to avoid
mis-priming, primer self-annealing or the formation of non-
specific PCR products that could affect the accuracy ofmethy-
lation detection. Each assay was optimised using an anneal-
ing temperature gradient, various concentrations of MgCl2
and primer, as well as different PCR cycling conditions. The
optimisation of the assay designed for the BLM2 marker
was very challenging, with the amplification efficiency be-
ing very low at all tested PCR conditions and it was decided
that this marker is excluded from further analysis. Failure
to optimise this particular assay is believed to be due to its
complex, CpG-rich DNA sequence. All other 11 assays per-
formedwell resulting in the detection of only the desired PCR
product.
Briefly, each PCR reaction consisted of 12.5 L of Zy-
moTaq PreMix, 1 L of 25 mM MgCl2 for a final concentra-
tion of 2.75 mM (since the ZymoTaq
TM
Premix also contains
1.75 mM MgCl2), 1 L of each PCR primer (for a final con-
centration of 0.4 M), 1 L of bisulphite DNA template and
8.5 L of nuclease-free water, for a total reaction volume
of 25 L. The thermocycling program used was as follows:
95°C for 10 min, followed by 45 cycles of 94°C for 30 s, Tm
for 30 s (SEU1—48°C (where stands for semen unmethy-
lated marker), BLU1—50°C (where BLU stands for blood
unmethylated marker), BLM1, BLU2, SEM1 (where SEM
stands for semen methylated marker), BUM1 (where BUM
stands for buccal methylated marker), BUM2, BUU1 (where
BUU stands for buccal unmethylatedmarker), BUU2—55°C,
SEM2—57°C and SEU2—61°C), 72°C for 35 s and a final ex-
tension step of 72°C for 2 min. Specifically for BLU1, BUM1,
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Table 1. Designed bisulphite PCR assays
Assay CpGs Primer sequence (5′→3′) Length (bp) GC (%) Converted Cs PCR product (bp)
BLM1 4 F TAGTTGATATTGGTTTGGTA 20 30 5 159
R CAAATAACTCAATTTCTCTAC 21 28.6 3
BLM2 2 F AAGTGTTGGGATTTTAGGAGT 21 38.1 2 180
R CCTCTTAATTTTCTTTTAAAAAC 23 21.7 1
BLU1 3 F GGTTTATTGTTTTGTATTAT 20 20 6 127
R AAATTCTCCAACACCACC 18 44.4 2
BLU2 5 F GAGTTATTTTTTTTGGTGTTGGAT 24 29.2 8 188
R ACATCCCCTTAAATTACTTT 20 30 4
SEM1 3 F ATGATTTAGTGGTTGGTAGGAA 22 36.4 3 147
R AACACCCCTAAAAAAAAC 18 33.3 7
SEM2 3 F AGTAAGTAGGAAGTGAATTGA 21 33.3 3 89
R ATATCTCAAAACAACCCAAA 20 30 6
SEU1 10 F TTTTATTAGAAAGTTTAGG 19 21.1 7 280
R ACAACAATAACTAAAAATAAATAC 24 16.7 6
SEU2 5 F GGAGGTTGTTTTTTTTTTGGTTT 23 30.4 6 134
R CTACCAACACCTTCCTCC 18 55.6 1
BUM1 6 F GTAGAGTTTTATTTTTTGTT 20 20 7 357
R CTCCTCCACCATAACCTA 18 50 3
BUM2 4 F TAGAGATAGATGGGTTTG 19 36.8 3 112
R CTAAATTCCTACAATATTCC 20 30 4
BUU1 1 F GAAAGGTGAGTTATAGAATAGTT 23 30.4 3 198
R CAAAATAAATCTCTCCCTT 19 31.6 2
BUU2 2 F TTGAGATGTTATAAGAGTATTGG 23 30.4 5 196
R ACTACTCCCTAAAAAAAC 18 33.3 7
BUM2, BUU1 and BUU2, the annealing and extension step
of each cycle was 40 s. Following amplification, the quality of
PCR products was assessed on a 2% agarose gel.
2.6 Template preparation for Pyrosequencing R©
reactions
PCR products were converted to single-strands through
biotin-streptavidin selective binding: 10 L of PCR products
were mixed with 3 L of Streptavidin Sepharose High Per-
formance Beads (GE Healthcare) and 37 L of PyroMark
Binding Buffer (Qiagen) as well as 30 L of distilled water for
a total volume of 80 L. The solutions were then vortexed at
1000 rpm for 30 min using a clear non-skirted 96-well plate
(Starlab) to allow for efficient binding of the PCR products to
the beads. Afterwards, the beads were isolated and captured
utilising a Vacuum Prep Workstation (Qiagen) according to
the manufacturer’s recommendations. Sequencing reactions
were performed bymixing the single-stranded templates with
11.5L of PyroMark Annealing buffer (Qiagen) and 0.5L of
the appropriate 10 M sequencing primer. To ensure com-
plete denaturation of DNA templates, these were heated at
80°C for 3 min. Reactions were left at room temperature for
5 min in order for the sequencing primer to bind before load-
ing them on a PyroMark MD Pyrosequencer (Qiagen). All
four nucleotides together with the enzymes and substrates
(PyroMark Gold Q96 reagents; Qiagen) were placed into
the instrument before analysis following the manufacturer’s
instructions.
Technical issues that needed to be resolved in this step
included wide peaks, peaks with ‘ski-slope’ effect or low
signal detected for the internal ‘dead dispensations’, all of
which were eliminated following optimisation of the pyrose-
quencing reactions. Supporting Information Fig. 1 illustrates
example pyrograms
TM
for all designed assays as obtained
from the analysis of one blood sample. Generally, and as
expected, the developed assays demonstrated different PCR
efficiencies as indicated by the peak heights, with SEU1 show-
ing on average the lowest peak heights taking into account all
samples.
2.7 Data analysis
Only pyrograms
TM
passing the instrument’s quality control
were used for analysis; this included the detection of desired
peaks (no signals in dead injections) as well as detected bisul-
phite conversion rates of 95%. Bisulphite conversion rates
were calculated using the peak heights of thymine and cy-
tosine of each bisulphite conversion control (non-CpG site
cytosines) and were on average 98%. If bisulphite conver-
sion rates were lower than 95%, the treatment with sodium
bisulphite was repeated. For each CpG site, the degree of
methylation was measured as a frequency of C/T signals
in the form of peak heights. Pyrosequencing
R©
dispenses
both thymine (T) and cytosine (C) for each CpG site; the
peak height of thymine corresponds to the unmethylated
sequence (C), whereas the peak height of cytosine corre-
sponds to the methylated sequence (mC). The principle of
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methylation detection can be described by the ratio of mC:C
at each CpG site using the following formula:
%Methylation =
[(
Peak height C
)
/
(
Peak height C + Peak height T)] × 100
For this analysis, the dedicated CpG methylation soft-
ware PyroMark CpG SW 1.0 (Qiagen) was employed. De-
tected methylation data distribution was visualised by em-
ploying box-and-whisker plots. Lastly, for themost promising
markers and as mentioned above, DNA standards of known
methylation levels (0–100%) were used to assess the linearity
ofmethylation quantification. The observedmethylation ratio
was plotted against the expected and the best-fitted regression
line (linear) was chosen. For data analysis, the IBMSPSS v.22
software was employed.
3 Results
3.1 Selection of genetic loci
In order to identify potential CpG sites of interest, the average
methylation level of each tissue for every CpG site was used.
Initially, the criterion of choosing suitable CpG sites was set
as a minimum of 70% methylation difference between the
tissue in question and the remaining two, demonstrating an
‘on/off’ methylation pattern. For example, a ‘good’ blood-
specific marker would be one that showed to be methylated
in blood (80%) and unmethylated in sperm and buccal cells
(10%) or vice versa. As a result, 14 blood-specific, 20 saliva-
specific and 365 semen-specific CpG sites were identified.
The number of semen-specific CpG sites was relatively high,
which could reflect the different and unique functions of
sperm DNA; thus, for semen only, the minimum difference
of methylation levels was increased to 85% and the number
of potential CpG sites chosen decreased to 22. Both tissue-
specific methylation and de-methylation were observed, al-
though the latter was observed comparatively more often.
Supporting Information Table 2 summarises the observed
methylation values for the top candidate markers for these
three tissues.
For the purpose of this study, four CpG sites demon-
strating the highest methylation difference between the
above-mentioned tissues were selected for each body fluid
(two unmethylated and two methylated markers) provid-
ing a total of 12 potentially tissue-specific CpG sites for
the Pyrosequencing
R©
assay design (Supporting Information
Table 3). The online Ensembl genome browser, and in partic-
ular the humanGRCh37/hg19 genome, was used to obtained
the required genetic information for assay design. The exact
chromosomal locations were confirmed and the surrounding
DNA sequences were identified. Information on the genes
and their function, as well as known SNPs included in the
regions of interest, was also obtained. Most of the selected
CpGs belong to protein-coding genes and are usually located
within their 5′ end or within the main body of the gene.
3.2 Verification of methylation patterns using
pyrosequencing
To verify the DNA methylation patterns of the selected
CpG sites reported by Rakyan et al. [6, 8] and confirm that
they are specific for blood, semen and buccal cells (Support-
ing Information Table 3), a set of samples were analysed for
each assay. It was important to confirm the methylation lev-
els of the proposed CpG sites in these three types of tissues
first, before any analysis is performed using other forensi-
cally relevant tissues such asmenstrual blood or vaginal fluid.
However, since the reason for choosingmarkers differentially
methylated in buccal cells was their potential use in the iden-
tification of saliva, a set of saliva samples were co-analysed.
The aim of this experiment was not only to verify the previ-
ously reportedmethylation but also perhaps potentially select
the best CpG sites of each assay for further validation. Most
assays also investigate themethylation status of adjacent CpG
sites and their potential in identifying the tissue of origin was
also tested. For this analysis, 1 ng of each DNA sample was
bisulphite treated and eluted in 20 L, followed by the am-
plification of all 11 assays in singleplex reactions. Depending
on the assay and the number of different tissues tested, the
number of samples analysed per assay ranged from 50 to
110 aiming for at least ten samples per tissue.
3.2.1 Potential saliva-specific CpG sites
The markers cg15731815 (BUM1) and cg08258650 (BUM2)
have been reported to be methylated in buccal cells (0.84
and 0.77 proportionately), while demonstrating low methy-
lation levels in blood and semen (0.05–0.08) (Supporting
Information Table 3). Although in the current study the
expected methylation status in blood and semen was con-
firmed, the methylation ratio in buccal cells in this study
was lower (average of 0.47 and 0.48 accordingly) (Fig. 1A
and B). Therefore, we can report that both these markers
can act as buccal-specific markers as there is still a suffi-
cient difference compared to blood and semen. However,
the analysis of saliva samples resulted in methylation lev-
els ranging from 0 to 0.4 (mean of 0.17 and 0.12, respec-
tively); although higher than blood and semen, it is believed
that this methylation difference is too narrow for conclu-
sive results. Finally, given that the identification of buc-
cal cells in a forensic scenario is not frequently applicable,
these markers were excluded from further analysis. Addi-
tionally, the marker cg05761971 (BUU1) had been previously
reported to be unmethylated in buccal cells (0.11), while be-
ing highly methylated in blood and semen (0.87 and 0.88,
respectively). Similar to above, the methylation difference
in this tissue was smaller than expected as we found an
average methylation ratio of 0.37 in buccal cells (Fig. 1C).
Furthermore, BUU1 also demonstrated a very large inter-
individual methylation variation when saliva was analysed
(n= 15), hence itwas concludednot suitable for saliva identifi-
cation.Moreover, although cg16779976 (BUU2) was reported
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Figure 1. Methylation levels of proposed buccal cell specific markers. Observed methylation ratio of each CpG site (A-BUM1, B-BUM2,
C-BUU1 and D-BUU2). Data are presented in the form of box-and-whisker plots showing the first and third quartiles (boxes), the median
(horizontal line) and minimum and maximum (error bars) methylation values detected. Outliers (methylation value 3SD) are shown
separately as ‘x’ dots.
to be methylated in both blood and semen by genome-wide
analysis, this observation was not confirmed in this study.
The methylation levels of buccal cells and saliva were similar
and slightly lower than the other two body fluids but not dis-
criminatory enough to include the marker in further analysis
(Fig. 1D).
In conclusion, although the methylation patterns of
three out of four selected CpG sites were successfully ver-
ified in blood and semen, the methylation difference com-
pared to buccal cells was smaller than previously reported.
Additionally, it was clear that saliva did not share the same
methylation profile with buccal cells but, especially for BUM1
and BUM2, gave very similar methylation values with blood.
This leads to the conclusion that possible presence of leuco-
cytes in saliva (e.g. due to gum bleeding) could be the reason
for such observation. It has previously been shown that up
to 74% of the recovered DNA in saliva can come from white
blood cells [19]. The amount of ‘contaminating’ blood cells or
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other cell types rather than buccal cells in saliva could vary be-
tween individuals and this could potentially explain the large
inter-individual methylation ratio observed in some cases.
3.2.2 Potential blood-specific markers
Although there were a total of four potentially blood-specific
CpG sites initially selected, only three of them could be veri-
fied since the BLM2 PCR assay failed the optimisation step.
CpGs cg17518965 (BLU1) and cg26285698 (BLU2) were re-
ported to be non-methylated in blood (0.02 and 0.09, respec-
tively) while being highly methylated in semen and buccal
cells (0.86–0.96). In this study, the methylation profile of
blood was confirmed, however the methylation levels in se-
men andbuccal cells demonstrated large inter-individual vari-
ation (Fig. 2A and B). Furthermore, saliva samples once again
demonstrated very lowmethylation, even though it was origi-
nally thought that they would be methylated at these two cho-
sen CpG sites. Even though, it was thought that BLU1 could
act as a semen-specificmarker, it was decided it was not desir-
able to have similar methylation profiles in semen and buccal
cell samples from a forensic perspective, and especially in
cases of complex or mixed stains. Tests of a small number
of vaginal and skin samples resulted in similar methylation
values as buccal cells, which could be explained by the shared
epithelial tissue origin (data not shown).
Interestingly, therewere two semen samples that showed
very lowmethylation (outliers, Fig. 2A), either because of nat-
ural variation in methylation levels (16.7% of semen samples
tested) and/or possible presence of blood in semen. Previous
research has reported the presence of white blood cells in
semen samples of infertile men or men with bacterial infec-
tions [20]. This could be partially supported when comparing
the DNA yield following DNA isolation using the same star-
ing material from all semen samples. These two samples
resulted in a tenfold decrease in DNA yield compared to the
average yield, potentially indicating a smaller number of sper-
matozoa present. Lower sperm count is often associated with
infertility problems and it has been previously shown that
alternations in sperm DNA methylation at particular loci are
common with low spermmotility and different types of male
infertility [21–23].
On the other hand, the findings regarding the third
marker cg13763232 (BLM1) were more promising. Ini-
tial results analysing the four tissues revealed a distinct
blood methylation profile as all blood samples resulted in
0.85 methylation ratio while semen and buccal cells ver-
ified the expected low methylation (0.12 and 0.21, respec-
tively) (Fig. 2C). Even though the methylation levels of saliva
samples ranged between 0.16 and 0.87 (mean = 0.60), it
was decided that the investigation of other forensically rele-
vant tissues was vital before final conclusions regarding this
marker’s specificity are made. Thus, an additional set of 34
samples (nine vaginal fluid, 14menstrual blood, five skin and
six urine samples) were analysed, the detected methylation
levels of which are shown in Fig. 2C.
As results revealed, BLM1was shown to be highlymethy-
lated only in blood, while the rest of the tested tissues
demonstrated various profiles being either non-methylated or
partially methylated. Similar methylation patterns were also
obtained for the three adjacent CpG sites, indicating a shared
profile within the locus. However, and for example in the case
of skin samples, a wide range of methylation ratio (0.13–0.94)
was observed. From a forensic perspective and considering
that skin/’touch DNA’ contamination often occurs in surface
swabs, employing the BLM1 assay would not be sufficient to
confirm the possible presence of a minute bloodstain with
confidence.
3.2.3 Potential semen-specific markers
For the identification of semen, two (cg04382920-SEU1 and
cg11768416-SEU2) reported to have nomethylation in semen
(0.02) and two (cg01318557-SEM1 and cg05656364-SEM2)
with more than 0.9 methylation were tested. The exact oppo-
site methylation status was shown in blood and buccal cells.
These patterns were successfully verified indicating the po-
tential of these CpGs in the identification of semen.However,
to establish their specificity a total of 110 samples includ-
ing various tissue types were analysed (Fig. 3). When testing
for SEM1 and SEM2, all non-semen tissues including whole
blood, buccal cells, saliva, vaginal fluid, menstrual blood, skin
and urine demonstrated very low levels of methylation, while
semen resulted in amean of 0.40 and 0.59, respectively. How-
ever, as shown in Fig. 3A and B, there was a largemethylation
range among semen samples.
Occasionally, in SEM1 there were a few outliers obtained
for blood, saliva and urine, which is believed to be due to
natural methylation variability; for urine, the presence of con-
taminating semen cannot also be excluded since the partic-
ular sample belongs to a male volunteer. Although semen
clearly demonstrated a different distribution in methylation
compared to other tissues, it was believed that the observed
outliers could introduce uncertainties in confirming semen
using this CpG site. Similarly, for SEM2 there were two
saliva samples resulting in 0.32 and 0.35 methylation ratio,
respectively, while there were two semen samples that were
found completely unmethylated. Interestingly, these two se-
men samples were the same with the ones showing an ‘op-
posite’ methylation profile in the BLU1 assay and were the
ones with low sperm count. Since these samples represent
15% of the total analysed semen samples, it was thought that
this marker will not be included in further validation in this
study, but increasing the sample size in future studies is vital
to assess how significant these outliers are.
On the other hand, as illustrated in Fig. 3C and D, both
SEU1 and SEU2 seemed to be highly specific markers for
semen. The results of the genome-wide methylation analy-
sis were confirmed for both markers, although the obtained
methylation for SEU2 innon-semen tissueswas slightly lower
than originally reported (0.75). There was one saliva sample
(5%) that showed low methylation levels, but this is believed
C© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
8 A. Vidaki et al. Electrophoresis 2016, 00, 1–13
Figure 2. Methylation levels of proposed blood-specific markers. Observed methylation ratio of each CpG site (A-BLU1, B-BLU2 and
C-BLM2). Data are presented in the form of box-and-whisker plots showing the first and third quartiles (boxes), the median (horizontal
line) and minimum and maximum (error bars) methylation values detected. Outliers (methylation value 3SD) are shown separately as
‘x’ dots.
to be due to natural methylation variability. Thus, we can
conclude that using these two CpG sites (SEU1 and SEU2)
no false negative results were obtained and only one out of
the total 154 non-semen samples resulted in a false-positive
identification of semen, which is particularly important in a
forensic scenario. Interestingly, most of the co-analysed adja-
cent CpG sites (nine CpGs in SEU1 assay and four CpGs in
SEU2 assay) also demonstrated the observed semen-specific
methylation pattern; therefore, they can be used all together
as semen-specific loci. In this study, we aimed for the highest
methylation difference possible (on/off methylation), which
for these two assays was successfully obtained. However, the
threshold of the methylation differences between the semen
andnon-semen sampleswasCpGspecific, with somedemon-
strating higher average differences (0.7).
3.3 Validation of semen-specific assays (SEU1 and
SEU2)
As previously shown, CpGs cg04382920 (SEU1) and
cg11768416 (SEU2) demonstrated a semen-specific DNA
methylation profile; however, in order to implement such
markers in forensic casework, extensive validation of the as-
sociated methylation assays is required. Initial validation of
these assays included testing their accuracy through linearity
C© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
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Figure 3. Methylation levels of the proposed semen-specific markers. (A) Number of samples used and (B) observed methylation ratio
of each CpG site (SEM1, SEM2, SEU1 and SEU2) in various body fluids/tissues. Data are presented in the form of box-and-whisker plots
showing the first and third quartiles (boxes), the median (horizontal line) and minimum and maximum (error bars) methylation values
detected. Outliers (methylation value 3SD) are shown separately as ‘x’ dots.
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analysis, sensitivity as well as testing aged semen to evaluate
potential applicability in cold cases.
3.3.1 Linearity of methylation quantification
To assess the accuracy of SEU1 and SEU2 assays, 100 ng of
each DNAmethylation control (0–100%) was analysed in du-
plicate. The mean and standard deviation of each standard
was then calculated taking into account all CpG sites in-
cluded in the sequences (10 CpGs in SEU1 and five CpGs
in SEU2) and used to assess the linearity of quantifying
methylation ratios. As shown in Supporting Information
Fig. 2, both assays resulted in linear quantification (SEU1:
R2 = 0.97 and SEU2: R2 = 0.99) and therefore no evi-
dence of amplification bias commonly observed in other
bisulphite PCR assays in the literature [24]. Methylation
quantification was more challenging and less accurate when
analysing partially methylated standards, which could be ex-
plained by stochastic variations or pipetting errors during
amplification.
3.3.2 Sensitivity analysis
The sensitivity of the proposed semen-specific methylation
assays was assessed by analysing decreasing amounts of start-
ingDNAmaterial (10ng, 1ng, 500pg, 100pg, 50 pg and10pg)
in duplicate. For this experiment, non-semen DNA (blood)
was used to assess if false-positive results would be obtained
due to the low amounts of DNA used. As shown in Support-
ing Information Fig. 3A, successful amplification and the
expected blood methylation pattern for SEU2 was obtained
with as low as 50 pg of starting DNA, which corresponds to
around ten cells. In particular, for the semen-specific CpG
site cg11768416, the detected DNA methylation levels were
constantly highly methylated for all tested amounts (ranging
from 0.87 to 0.97), which fully corresponds to the expected
bloodmethylation of thismarker as obtained in the specificity
experiment (Fig. 3). This small variation in DNAmethylation
as resulted when using decreasing starting DNA amount was
also obtained for the neighbour CpGs in the SEU2 assay.
This is very promising for the analysis of low-quantity or
degraded samples, indicating the assay’s potential applicabil-
ity in forensic casework. Bisulphite conversion, as the first
step of the proposed method, is essential in determining the
overall sensitivity of bisulphite pyrosequencing assays. In our
experiments, the detected conversion seemed to be slightly
affected by the starting DNA amount, nevertheless an aver-
age of 91.5% conversion using all three controls included in
the SEU2 assay was obtained for all amounts (Supporting
Information Fig. 3B). It should be noted that for the first
bisulphite control, conversion rates were higher (average of
96.2%) while the third control resulted in a mean rate of
85.4%. It is believed that this is due to low S/N (low peak
heights) or due to signal carry over from previous unincor-
porated cytosines. Similar results were obtained also for the
SEU1 assay, where for all amounts highmethylation levels of
cg04382920 (92%) were detected in blood (data not shown).
3.3.3 Stability of CpG methylation and aged samples
To further test the SEU1 and SEU2 markers’ DNA methy-
lation stability as well as the assays’ potential applicability
in forensic casework, a set of aged and potentially degraded
samples were tested. DNA from a set of nine semen samples
was extracted shortly after collection and following storage at
–20°C for 1 year. Although the obtained DNA amount per
extracted microlitre of semen decreased over time, follow-
ing the treatment of 10 ng of DNA the methylation status
for all semen samples was found to be 0.2 methylated in
both loci. No significant difference was obtained between the
methylation values of fresh and stored semen samples (p 
0.05). In addition, a set of four semen stains on fabric (cot-
ton) stored at –20°C for almost 16 years were also analysed.
No false-negative results were obtained as all four semen
stains produced low methylation levels (0.1). Furthermore,
together with the semen stains, another five blood stains on
fabric (cotton) stored at ambient temperature for more than
20 years were analysed. Once again, no false positive results
were obtained as all five blood stains gave high methylation
levels (0.6), despite their lower peak heights (70 rfus),
which could be explained by the low DNA quantity recovered
from these stains. The detected methylation patterns for both
semen and bloodmatched those obtained by freshly collected
body fluid samples, highlighting the stability of DNA methy-
lationwhen samples are stored both at room temperature and
–20°C.
4 Discussion
Although forensic researchers have investigated in depth the
potential of applying mRNA profiling in tissue identifica-
tion [2, 25] and research on developing robust assays is still
ongoing [26, 27], it is thought that in certain forensic sce-
narios, such as in cold cases or cases that involved degraded
stains, its application would not be feasible. For this purpose,
DNA methylation patterns among tissues were evaluated for
their potential in differentiating tissues. Over the last few
years, both the potential and challenges of such approach
have been apparent [10, 13]. As an example, even though
Frumkin et al. proposed the use of seven loci for the simul-
taneous identification of blood, semen, saliva, skin, urine,
menstrual blood and vaginal secretion, it was reported by
Gomes et al. that they failed to reproduce their results on skin
identification [28].
It is known that DNA methylation regulates gene ex-
pression and controls cellular differentiation during develop-
ment [4, 29]; however, in the medical field differential epi-
genetic patterns among tissues are mainly assessed in order
to evaluate if observed differential patterns in diseased tis-
sues are meaningful events or part of natural tissue-to-tissue
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variation. The main challenge faced in this study regarding
the identification of suitable CpG sites based on publicly
available datasets was the lack of methylation data in forensi-
cally relevant body fluids such as vaginal fluid and menstrual
blood. Therefore, an extensive validation of the selectedmark-
ers as well as the identification of novel ones was needed
to assess their specificity. However, it was not only the se-
lection of previously reported differentially methylated CpG
sites that was necessary but also the development of amethod
that would allow for the amplification and sequencing of
shorter fragments. This ability would increase the proposed
method’s applicability in forensic casework where samples
are often of low quality/quantity. The capability of bisulphite
Pyrosequencing
R©
to quantifymethylation levels has been pre-
viously assessed [30] and its advantages over other methods
have also been established [31].
Analysis of genome-widemethylation data gathered from
blood, semen and buccal cell samples identified a set of
11 body fluid specific CpG sites. In this case, following analy-
sis with bisulphite Pyrosequencing
R©
only the selected semen
markers were confirmed as suitable. This is due to similar
methylation profiles being detected among blood and saliva
samples, which supports the likely presence of white blood
cells in saliva, further supported by the observed difference
in methylation between buccal cells and saliva. Nevertheless,
cg13763232 (BLM1) demonstrated very high methylation lev-
els (0.85) only in whole blood and could potentially be
used to exclude the presence of menstrual blood, although
a larger study is required before conclusions are made. In-
terestingly, this CpG site belongs to the promoter region of
the solute-carrier family 6, member 6 (SLC6A6) gene that
encodes for a sodium- and chloride-dependent transporter
of the neurotransmitters taurine and beta-alanine [32]. Tau-
rine plays an important role in many biological activities in-
cluding osmoregulation, membrane stabilisation and anti-
oxidation [33]. It has been reported that this gene is regulated
by controlling transcription factor binding sites in its pro-
moter; therefore, the involvement of DNA methylation in
this control cannot be excluded.
As shown in similar studies [13, 14, 34], identifying
semen-specific methylation patterns has shown to be rather
simple. This comes as no surprise since sperm cells have a
unique composition in terms of histones and proteins. This
was highlighted further for DNA methylation, since initial
selection of highly differentially methylated sites between se-
men and blood/buccal cells using the genome-wide methy-
lation data obtained by Rakyan et al. [6, 8] resulted in hun-
dreds of potential markers. All four tested CpG sites demon-
strated semen-specific differential methylation; however, two
of them (cg01318557-SEM1 and cg05656364-SEM2) did not
seem to be sufficiently robust.
Looking at the biological functions of the involved genes
for the best two semen-specific CpG sites to help understand
and justify the observed differential methylation in semen,
some interesting observations can be made. The sequence
analysed by the SEU1 assay belongs to a gene encoding for
the solute carrier family 25 (mitochondrial carrier; adenine
nucleotide translocator), member 31 protein (SLC25A31),
which catalyses the exchange of cytoplasmic ADP with mi-
tochondrial ATP across the mitochondrial inner membrane.
It is believed that it mediates energy generating and energy
consuming processes in the distal flagellum, possibly as a
nucleotide shuttle between flagellar glycolysis, protein phos-
phorylation and mechanisms of motility [35]. It has previ-
ously been reported that its SLC25A31 mRNA transcripts are
exclusively present in liver, testis and brain [35]; therefore,
differential DNA methylation in its promoter (where SEU1
is found) could regulate its expression. A recent study sup-
ports this assumption, as SLC25A31 was found to be one of
the few differentially methylated genes in semen following a
genome-wide analysis of 38 semen samples [36]. It was re-
ported to be involved in spermatogenesis and associated with
inflammation and autoimmune processes interfering with
fertility. Moreover, cg11768416 (SEU2) belongs to the gene
encoding for the coiled coil glutamate rich protein 1 (Ccer1
or C12orf12). Remarkably, this gene has been previously re-
ported to have dense promoter CpG island methylation and
gene silencing in normal tissues except testis and sperm [29];
a finding that was confirmed in this study. Authors tested var-
ious healthy and diseased tissues and found that hypomethy-
lation of this gene in non-semen tissues is associated with
gene activation in cancer.
Furthermore, using the proposed markers, successful
detection in aged stains of up to 16 years as well as high
sensitivity (using as little as 50 pg of starting DNA mate-
rial) was obtained making their application in forensic case-
work possible. Even though both PCR assays resulted in a
linear DNA methylation quantification, future validation ex-
periments are necessary in order to determine whether PCR
bias occur when using very low DNA input. The sensitivity
of DNA methylation assays for tissue identification have also
been demonstrated in the study by LaRue et al. [12], where
positive results for semen were obtained when using as low
as 31 pg using the proposed DSI-Semen
TM
kit developed by
Wasserstrom et al. [11]. Future experiments using semen
stains of decreasing size (as measured in microlitres) would
fully determine the assays’ sensitivity proposed in this study.
Novel next-generation sequencing (NGS), including various
NGS platforms, has been increasingly used in the forensic
field and recent studies have also investigated its applica-
bility in tissue identification using DNA methylation mark-
ers [37, 38]. Applying NGS could significantly increase the
sensitivity and also allow for analysis of an increased number
of tissue-specific markers included in a tissue-ID assay.
It should be noted that caution is needed when apply-
ing DNA methylation markers for tissue identification since
changes in DNA methylation patterns have been reported
in various diseases [39, 40]. With regard to semen detection,
it has been shown that alterations in sperm DNA methyla-
tion patterns in particular loci are associated with low sperm
motility and different types of male infertility [21–23]. In fact,
in this study there were two semen samples in particular that
showed an ‘unexpected’ methylation ratio for most semen-
specific assays tested. The observations above, including the
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implication of some of these markers in cancer via an ‘abnor-
mal’ methylation profile as well as the possible ‘connection’
between low sperm counts and altered methylation levels,
highlights the need for validation of the proposed markers
prior to implementation by analysing diseased samples. Ide-
ally, together with samples from ‘healthy’ volunteers, sam-
ples from patients suffering from various diseases should
be co-analysed so that a better representation of the general
population is achieved. Because of the ethical restrictions,
gathering personal data regarding disease status from crime
scene stains is not permitted; therefore, all possible reasons
that could lead to alteredmethylation profiles should be taken
into account.
Additionally, it can be concluded that an important draw-
back of applying DNA methylation profiling into forensic
casework is the analysis of mixed stains. Since DNA methy-
lation results are presented in a more quantitative manner
compared to the mRNA profiling (percentages rather than
the presence/absence of peaks), a result regarding one tissue-
specific marker would be insufficient to report the tissue
source. Therefore, a serial analysis including at least two or
three CpG sites per tissue (similar to proposed mRNA strate-
gies) would be necessary in order to include or exclude the
presence of a body fluid and marker-specific ratios employed
to investigate possible mixed stains. Future work regarding
the tissue-specific DNA methylation profiling could include
not only an extensive validation of the blood- and semen-
specific markers found in this study but also the potential
development of a multiplex PCR assay capable of amplify-
ing all proposed markers in one test, which is more desir-
able in a forensic setting. Furthermore, future research could
consider the investigation of more genomic loci showing po-
tentially better tissue-specific DNA methylation patterns. To
account for potential, common inter-individual differences
in DNA methylation and, consequently, gene expression, a
larger dataset of body fluids and tissues should be collected.
4.1 Conclusion
In conclusion, DNAmethylation profiling for use in detecting
body fluids and tissues seems promising. Evaluation of the
bisulphite Pyrosequencing
R©
-based assays revealed that this
method can be highly sensitive; successful DNAmethylation
profiles were obtained with as low as 50 pg of starting ma-
terial. In general, it was observed that semen demonstrated
clear, differential DNA methylation patterns and was easy
to detect with confidence. The two proposed semen-specific
markers performed well in mock casework and their DNA
methylation profiles were stable for up to 16 years in semen
stains.
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